Which hypoglycaemic treatment?;Quale terapia ipoglicemizzante?

Giornale di Gerontologia

Volumn 52, Issue 5, 2004, Pages 322-325

  Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cardiovascular risk; Diabetes mellitus; Hypoglycaemic treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; VASCULAR DISEASE;

EID: 25444477846     PISSN: 00170305     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. DCCT Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
4. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of microvascular and macrovascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-13.
5. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.
6. Van den Berghe G, Wouters P, Weekers; F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:675-82.
7. UK Prospective Diabetes Study (UKPDS) Group. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
8. Hanefeld M, Cagatay M, Petrovitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk of myocardial infarction in patients with type 2 diabetes: a meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.
9. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care 1999;22:960-4.
10. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:135.
11. Mannucci E, Monami M, Masotti G, Marchionni M. All cause mortality in patients treated with combinations of sulphonylureas and biguanides. Diabetes-Metabolism Res Rev 2004;20:44-7.